







THE

 FOUNDATION

	 Soliris® (eculizumab)	 Uplizna™ (inebulizumabcdn)	 Enspryng® (satralizumab)
PHARMACOLOGY	Complement Inhibitor	B Cell Depletion	Interleuken-6 (IL-6) Inhibitor
DRUG DELIVERY METHOD	Infusion (35 minutes)	Infusion (90 minutes)	Subcutaneous Injection
FREQUENCY	Every 2 weeks	Every 6 months	Every 4 weeks
DOSAGE	1200 mg	300 mg	120 mg
REDUCTION IN RELAPSE RISK	94%	77% *monotherapy without background therapy	79% with background therapy, 74% without background therapy
ANTIBODY CRITERIA	AQP4+ NMOSD (MOG untested)	AQP4+ NMOSD (MOG untested)	AQP4+ NMOSD (MOG untested)
COMMON SIDE EFFECTS	Headaches Runny Nose	Urinary Tract Infection Joint Pain	Headaches Runny Nose
POTENTIAL SERIOUS SIDE EFFECTS	Important Safety Information and Indication for SOLIRIS (eculizumab)	Infusion reactions and infection	Infusion reactions and infection
MANUFACTURER			 <i>A Member of the Roche Group</i>
ASSISTANCE PROGRAMS	Alexion	Horizon By Your Side	Enspryng Co-Pay Program
PRESCRIBING INFORMATION	Soliris® Prescribing Information	Uplizna™ Prescribing Information	Enspryng™ Prescribing Information